Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
The stock has been choppy in the short term, with the share price down around 4.4% over the last week and 6.2% over the past month, but still showing a strong 84.7% gain over three years despite being down 55.5% over five years and 4.9% year to date. Recent headlines have focused on Zevra's progress in advancing its rare disease pipeline and strategic updates around its commercialization plans, which help explain why investors have been reassessing both its growth runway and risk profile. At the same time, regulatory and partnership developments have kept the stock on traders' radar as sentiment swings between optimism about future approvals and caution about execution risk. Against that backdrop, our valuation framework gives Zevra a 6/6 valuation score , suggesting it screens as undervalued on every one of our checks. Up next, we will break down how different valuation approaches stack up, before finishing with an even more intuitive way to think about what the stock might real
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewswire
- Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics announces CFO transition [Seeking Alpha]Seeking Alpha
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 12/9/25 - Form 4
- 12/9/25 - Form 3
- 12/2/25 - Form 8-K
- ZVRA's page on the SEC website